Radiolabeling, In Vitro Cell Uptake, and In Vivo Photodynamic Therapy Potential of Targeted Mesoporous Silica Nanoparticles Containing Zinc Phthalocyanine

Basit Öğe Kaydı
dc.authoridInce, Mine/0000-0002-9164-0446
dc.authoridTuncel, Ayca/0000-0003-0699-3309
dc.authoridAktas, Safiye/0000-0002-7658-5565
dc.authoridYurt, Fatma/0000-0002-9394-6908
dc.contributor.authorEr, Ozge
dc.contributor.authorTuncel, Ayca
dc.contributor.authorOcakoglu, Kasim
dc.contributor.authorInce, Mine
dc.contributor.authorKolatan, Efsun Hatice
dc.contributor.authorYilmaz, Osman
dc.contributor.authorAktas, Safiye
dc.date.accessioned2025-03-17T12:25:55Z
dc.date.available2025-03-17T12:25:55Z
dc.date.issued2020
dc.departmentTarsus Üniversitesi
dc.description.abstractPhotodynamic therapy (PDT) is a noninvasive therapy based on the photodynamic effect. In this study, we sought to determine intracellular uptake and in vivo photodynamic therapy potential of Zn phthalocyanine-loaded mesoporous silica nanoparticles (MSNPS) against pancreatic cancer cells. MSNPS were labeled with I-131; the radiolabeling efficiency was found to 95.5 +/- 1.2% in pH 9 and 60 min reaction time. Besides, the highest intracellular uptake yields of I-131-MSNPS nanoparticles in MIA PaCa-2, AsPC-1, and PANC-1 cells were determined as 43.9 +/- 3.8%, 41.8 +/- 0.2%, and 37.9 +/- 1.3%, respectively, at 24 h incubation time. In vivo PDT studies were performed with subcutaneous xenograft cancer model nude mice with AsPC-1 pancreatic cancer cells. For photodynamic therapy, 685 nm red laser light 100 J/cm(2) light dose using and 5-20 mu M ZnPc containing MSNPS concentrations were applied. Histopathological studies revealed that the ratio of necrosis in tumor tissue was higher in the treatment group than the control groups.
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) [2214/A]; Ege University, Scientific Research Project (BAP) [16 NBE 001]
dc.description.sponsorshipThis research was funded by the Scientific and Technological Research Council of Turkey (TUBITAK; grant number2214/A), Ege University, Scientific Research Project (BAP; grant Number: 16 NBE 001).
dc.identifier.doi10.1021/acs.molpharmaceut.0c00331
dc.identifier.endpage2659
dc.identifier.issn1543-8384
dc.identifier.issn1543-8392
dc.identifier.issue7
dc.identifier.pmid32412765
dc.identifier.scopus2-s2.0-85087532477
dc.identifier.scopusqualityQ1
dc.identifier.startpage2648
dc.identifier.urihttps://doi.org/10.1021/acs.molpharmaceut.0c00331
dc.identifier.urihttps://hdl.handle.net/20.500.13099/1923
dc.identifier.volume17
dc.identifier.wosWOS:000548455300035
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherAmer Chemical Soc
dc.relation.ispartofMolecular Pharmaceutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WOS_20250316
dc.subjectZn(II) phthalocyanine
dc.subjectmesoporous silica nanoparticles
dc.subjectcetuximab
dc.subjectsinglet oxygen
dc.subjectphotodynamic therapy
dc.titleRadiolabeling, In Vitro Cell Uptake, and In Vivo Photodynamic Therapy Potential of Targeted Mesoporous Silica Nanoparticles Containing Zinc Phthalocyanine
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu